← Leaderboards
Donghui Li
University Of Texas Md Anderson Can Ctr
$4,233,878
Attributed
$7,160,031
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,160,031 · 6
By mechanism
R01$6,464,237 · 3
R21$382,800 · 1
R03$312,994 · 2
Top collaborators
- Christopher I. Amos7 shared
- Manal M Hassan7 shared
- Lewis R Roberts7 shared
- Michael J Overman2 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Manal M Hassan$2,411,596
- Frank A Sinicrope$7,695,451
- Scott M Lippman$54,535,308
- Xifeng Wu$28,679,533
- Sara S. Strom$4,426,461
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifeEnvironmental Risk FactorUnited StatesGeneticBaseEnrollmentCase-Control StudiesSamplingCase ControlEtiologyProgression-Free SurvivalsPathway InteractionsData SetPredispositionPatternSingle Nucleotide PolymorphismIncidenceGenetic Predisposition To DiseaseGenotypeMalignant NeoplasmsFutureRaceRecording Of Previous EventsResponse
Grant awards (19)
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)$602,699
R01 · FY2019 · CA
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)$620,205
R01 · FY2018 · CA
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)$165,134
R01 · FY2018 · CA
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)$655,272
R01 · FY2017 · CA
KRAS Muations in Plasma cfDNA as Predictor to Erolinib Response in Advanced Pancreatic Cancer$174,000
R21 · FY2017 · CA · contact PI
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)$113,799
R01 · FY2017 · CA
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)$657,227
R01 · FY2016 · CA
KRAS Muations in Plasma cfDNA as Predictor to Erolinib Response in Advanced Pancreatic Cancer$208,800
R21 · FY2016 · CA · contact PI
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)$832,002
R01 · FY2015 · CA
Dietary Nitrosamines and Risk of Pancreatic Cancer$77,227
R03 · FY2009 · CA · contact PI
Molecular Epidemiology of Pancreatic Cancer$1,020,222
R01 · FY2008 · CA · contact PI
Dietary Nitrosamines and Risk of Pancreatic Cancer$85,267
R03 · FY2008 · CA · contact PI
Molecular Epidemiology of Pancreatic Cancer$419,539
R01 · FY2007 · CA · contact PI
Molecular Epidemiology of Pancreatic Cancer$391,860
R01 · FY2006 · CA · contact PI
Molecular Epidemiology of Pancreatic Cancer$389,568
R01 · FY2005 · CA
Molecular Epidemiology of Pancreatic Cancer$407,780
R01 · FY2004 · CA
GENETIC SUSCEPTIBILITY--CARCINOGENS IN PANCREATIC CANCER$75,000
R03 · FY2001 · CA
DNA ADDUCT, P53 MUTATION, AND ETIOLOGY OF BREAST CANCER$188,930
R01 · FY2000 · CA
GENETIC SUSCEPTIBILITY--CARCINOGENS IN PANCREATIC CANCER$75,500
R03 · FY2000 · CA